-- Evofem now has four Orange Book listed
patents covering Phexxi into 2033 --
SAN
DIEGO, Feb. 27,
2023 /PRNewswire/ -- Evofem Biosciences, Inc.
(OTCQB: EVFM) today announced that two additional
U.S. patents which cover Phexxi® (lactic
acid, citric acid and potassium bitartrate) and its
labeled indication are now listed in the U.S. Food and Drug
Administration (FDA) publication Approved Drug
Products with Therapeutic Equivalence
Evaluations, commonly known as the Orange
Book.
"The Orange Book listing of these two patents covering
Phexxi's composition of matter and its method of use in
contraception is an important step in further strengthening our
patent portfolio," said Evofem Biosciences CEO Saundra Pelletier. "We plan to further expand
our intellectual property estate in the U.S. and overseas as we
continue to iterate our vaginal pH modulator platform and seek
entry into global markets."
The newly listed U.S. Patent No. 11,337,989 (the '989 patent)
covers contraception using the L-Lactic Acid Phexxi formulation.
The '989 patent was issued by the U.S. Patent and Trademark Office
(USPTO) on May 24, 2022 and is expected to expire in
March 2033.
The newly listed U.S. Patent No. 11,439,610 (the '610 patent)
covers compositions containing L-Lactic Acid, including the Phexxi
formulation. The '610 patent was issued by the USPTO
on September 13, 2022 and is expected to expire in March
2033.
About Evofem
Evofem Biosciences, Inc., is developing and commercializing
innovative products to address unmet needs in women's sexual and
reproductive health. The Company's first FDA-approved
product, Phexxi® (lactic acid, citric acid and potassium
bitartrate), is a hormone-free, on-demand prescription
contraceptive vaginal gel. It comes in a box of 12 pre-filled
applicators and is applied 0-60 minutes before each act of
sex. Learn more
at phexxi.com and evofem.com.
Phexxi® is a registered trademark of Evofem
Biosciences, Inc.
Forward-Looking Statements
This press release
includes "forward-looking statements," within the meaning of the
safe harbor for forward-looking statements provided by Section 21E
of the Securities Exchange Act of 1934, as amended, and the Private
Securities Litigation Reform Act of 1995 including, without
limitation, statements related to the expected duration of the
issued patents and Evofem's plans to further expand
its intellectual property estate, to iterate its vaginal pH
modulator platform, and to enter into global markets. You are
cautioned not to place undue reliance on these forward-looking
statements, which are current only as of the date of this press
release. Each of these forward-looking statements involves risks
and uncertainties. Important factors that could cause actual
results to differ materially from those discussed or implied in the
forward-looking statements are disclosed in the Company's SEC
filings, including its Annual Report on Form 10-K for the year
ended December 31, 2021, filed with the SEC on March 10,
2022, its Quarterly Report on Form 10-Q for the quarter
ended September 30, 2022 filed with the SEC
on January 6, 2023 and any subsequent filings. All
forward-looking statements are expressly qualified in their
entirety by such factors. The Company does not undertake any duty
to update any forward-looking statement except as required by
law.
Contact
Amy Raskopf
SVP, Investor Relations
Evofem Biosciences,
Inc.
araskopf@evofem.com / media@evofem.com
(917) 673-5775
View original content to download
multimedia:https://www.prnewswire.com/news-releases/evofem-biosciences-announces-fda-orange-book-listing-of-two-additional-us-patents-for-phexxi-301756268.html
SOURCE Evofem Biosciences, Inc.